Quantum Genomics Corp.

22 articles with Quantum Genomics Corp.

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: December 23-27

  12/30/2019

  With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
• 

  Clinical Catch-Up: September 9-13

  9/16/2019

  Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.

• Advances in Medicine Cause New, Groundbreaking Drug by Quantum Genomics (QNNTF) to Help With Chronic Hypertension

  8/4/2019

  Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system.

• The Association of Black Cardiologists collaborating with Quantum Genomics' NEW-HOPE Study, incorporating minority inclusivity, presents Late-Breaking Trial success of novel antihypertensive agent

  11/10/2018

  Firibastat meets primary endpoint and demonstrates highly significant and clinically relevant efficacy in lowering blood pressure in a diverse population whose hypertension is typically difficult to treat

• Edison Issues Initiation On Quantum Genomics Corp.

  11/30/2016

• Quantum Genomics Corp. Reports Positive Top-Line Results From Phase IIa Trial Of QGC001 In Hypertension

  9/30/2016

• Quantum Genomics Corp. Expands U.S. Presence To Advance Its Development Programs For Cardiovascular Diseases

  2/4/2016

• Quantum Genomics Corp. Announces Successful Phase Ia Data With QGC001, Its Lead Compound for the Treatment of Hypertension

  10/19/2012

• Quantum Genomics Corp. Announces Initiation of a First-in-Human Clinical Study With QGC001, Its Lead Compound for the Treatment of Hypertension

  4/13/2012

• Quantum Genomics Corp. Gets Approval from the Patients' Protection Committee

  1/5/2012

• Quantum Genomics Corp. (Nyse Euronext Paris: MLQGC) Announced Today Positive Scientific Results With Its Product QGC001

  4/1/2011

• Quantum Genomics Corp. (NYSE Euronext Paris: MLQGC) Announced Today that EUR 1.4 Million in Funding has Been Granted by the National Research Agency (ANR) for a Collaborative Research Project Named BAPAI

  2/2/2011

• Quantum Genomics Corp. Enters the NYSE-Euronext Market (MLQGC)

  7/28/2009

• Quantum Genomics Corp. Gets 1 Million $ (740 K€) From Oseo to Finance the Regulatory Preclinical Development of QGC 001

  4/2/2009

• Quantum Genomics Corp. Signs Strategic Agreement With PCAS To Make First Batch of Hypertension Drug Candidate

  7/8/2008

• Quantum Genomics Corp. Partners with INSERM in Stroke and Cardiac Ischemia Drug Development

  1/24/2008

• Quantum Genomics Corp. Widens Net with Acquisition of Eurobiobiz SAS

  10/29/2007

• Quantum Genomics Corp. Partners with INSERM and CNRS - Faculté de Médecine in Hypertension Drug Development

  6/28/2007